Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo

International Journal of Oncology

Volumn 32, Issue 2, 2008, Pages 475-480

  Sartippour, Maryam R ^a   Seeram, Navindra P ^a   Rao, Jian Yu ^b   Moro, Aune ^a   Harris, Diane M ^a   Henning, Susanne M ^a   Firouzi, Amita ^a   Rettig, Matthew B ^b   Aronson, William J ^b   Pantuck, Allan J ^b   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Hypoxia inducible factor 1 ; Pomegranate; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

ELLAGITANNIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLANT EXTRACT; POMEGRANATE EXTRACT; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUVEC CELL LINE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; POMEGRANATE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCID MOUSE; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 38849088073     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.2.475     Document Type: Article

References (37)

1. Forsythe JA, Jiang BH, Lyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxta-inducible growth factor 1. Mol Cell Biol 6: 4604-4613, 1996,
2. Harris AL: Hypoxia - A key regulatory factor in tumor growth, Nat Rev Cancer 2: 38-47, 2002,
3. Belozerov VE and Van Meir EG: Hypoxia inducible factor-1a: a novel target for cancer therapy, Anti-Cancer Drugs 16: 901-909, 2005.
4. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
5. Shannon AM, Bouchier-Hayes DJ, Condron CM and Toomey D: Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29: 297-307, 2003,
6. Wang GL and Semenza GL: Purification and characterization of hypoxia-inducible factor I, J Biol them 270: 230-1237, 1995,
7. Maxwell PH, Dachs GU, Gleadle JM, et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997.
8. Huang LE, Arany Z, Livingston DM and Buun HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
9. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
10. Salceda S and Caro J: Hypoxia-inducible factor lalpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilizationby hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
11. Kallio PJ, Wilson WJ, O'Brien S, et al: Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525, 1999.
12. 2 sensing. Science 292: 464-468, 2001.
13. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
14. Zhong H, Semenza GL, Simons JW and De Marzo AM: Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 28: 88-93, 2004.
15. Carmeliet P, Dor Y, Herbert JM, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998.
16. Ryan HE, Lo J and Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 3005-3015, 1998.
17. Mabjeesh NJ, Willard MT, Frederickson CE, et al: Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9: 2416-2425, 2003.
18. Afaq F, Saleem M, Krueger CG, Reed JD and Mukhtar H: Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-κB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer 113: 423-433, 2005.
19. Lansky EP, Jiang W, Mo H, et al: Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 23: 11-20, 2005.
20. Albrecht M, Jiang W, Kumi-Diaka J, et al: Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7: 274-283, 2004.
21. Seeram NP, Henning SM, Zhang Y, et al: Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours, J Nutr 136: 2481-2485, 2006.
22. Seeram NP, Lee R, Hardy ML and Heber D: Rapid large-scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. Sep Purific Tech 41: 49-55, 2005.
23. Schneider K, Oltmanns J and Hassauer M: Allometric principles for interspecies extrapolation in toxicological risk assessment -empirical investigations. Regul Toxicol Pharmacol 39: 334-347, 2004,
24. Sartippour M, Heber D, Lu Q, et al: Green tea and its catechins Inhibit breast cancer xenografts. Nutr Cancer 40: 149-156, 2001.
25. Sartippour MR, Seeram N, Heber D, et al: Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol 26: 121-127, 2005.
26. Sartippour MR, Shao ZM, Heber D, et al: Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 132: 2307-2311, 2002.
27. Sartippour MR, Pietras R, Marquez-Garban DC, et al: The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 27: 2424-2433, 2006.
28. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
29. Pantuck AJ, Leppert JT, Zomorodian N, et al: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2: 4018-4026, 2006.
30. Gil MI, Tomas-Barberan FA, Hess-Pierce B, et al: Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 48: 4581-4589, 2000.
31. Seeram NP, Aronson WJ, Zhang Y, et al: Pomegranate ellagitannin derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55: 7777-7785, 2007.
32. Sun HL, Liu YN, Huan YT, et al: YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene 26: 3941-3951, 2006.
33. Lee S, Jilani SM, Nikolova GV, et al: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169: 681-691, 2005.
34. De Marzo AM, Marchi VL, Epstein JI and Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155: 1985-1992, 1999.
35. Domingo-Domenech J, Mellado B, Ferrer B, et al: Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93: 1285-1294, 2005.
36. Malik A, Afaq F, Sarfaraz S, et al: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102: 14813-14818, 2005.
37. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.